| Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management S McPherson, T Hardy, E Henderson, AD Burt, CP Day, QM Anstee Journal of hepatology 62 (5), 1148-1155, 2015 | 1252 | 2015 |
| Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease S McPherson, SF Stewart, E Henderson, AD Burt, CP Day Gut 59 (9), 1265-1269, 2010 | 1004 | 2010 |
| Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis RS Taylor, RJ Taylor, S Bayliss, H Hagström, P Nasr, JM Schattenberg, ... Gastroenterology 158 (6), 1611-1625. e12, 2020 | 802 | 2020 |
| Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis S McPherson, T Hardy, JF Dufour, S Petta, M Romero-Gomez, M Allison, ... Official journal of the American College of Gastroenterology| ACG 112 (5 …, 2017 | 721 | 2017 |
| TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease YL Liu, HL Reeves, AD Burt, D Tiniakos, S McPherson, JBS Leathart, ... Nature communications 5 (1), 4309, 2014 | 716 | 2014 |
| Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging JK Dyson, QM Anstee, S McPherson Frontline gastroenterology 5 (3), 211-218, 2014 | 467 | 2014 |
| How big a problem is non-alcoholic fatty liver disease? QM Anstee, S McPherson, CP Day Bmj 343, 2011 | 258 | 2011 |
| Intravenous immunoglobulin for the treatment of severe, refractory, and recurrentClostridium difficilediarrhea S McPherson, CJ Rees, R Ellis, S Soo, SJ Panter Diseases of the colon & rectum 49 (5), 640-645, 2006 | 252 | 2006 |
| Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial D Houghton, C Thoma, K Hallsworth, S Cassidy, T Hardy, AD Burt, ... Clinical Gastroenterology and Hepatology 15 (1), 96-102. e3, 2017 | 250 | 2017 |
| Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered S McPherson, JR Jonsson, GJ Cowin, P O’Rourke, AD Clouston, A Volp, ... Journal of hepatology 51 (2), 389-397, 2009 | 237 | 2009 |
| Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease T Hardy, M Zeybel, CP Day, C Dipper, S Masson, S McPherson, ... Gut 66 (7), 1321-1328, 2017 | 216 | 2017 |
| Republished: non-alcoholic fatty liver disease: a practical approach to treatment JK Dyson, QM Anstee, S McPherson Postgraduate medical journal 91 (1072), 92-101, 2015 | 198 | 2015 |
| Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels? S McPherson, QM Anstee, E Henderson, CP Day, AD Burt European journal of gastroenterology & hepatology 25 (6), 652-658, 2013 | 135 | 2013 |
| Imagestream detection and characterisation of circulating tumour cells–A liquid biopsy for hepatocellular carcinoma? LF Ogle, JG Orr, CE Willoughby, C Hutton, S McPherson, R Plummer, ... Journal of hepatology 65 (2), 305-313, 2016 | 126 | 2016 |
| Management of decompensated cirrhosis D Mansour, S McPherson Clinical Medicine 18 (2), s60-s65, 2018 | 119 | 2018 |
| Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease S McPherson, E Henderson, AD Burt, CP Day, QM Anstee Journal of hepatology 60 (5), 1055-1062, 2014 | 116 | 2014 |
| Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease M Boyle, D Tiniakos, JM Schattenberg, V Ratziu, E Bugianessi, S Petta, ... Jhep Reports 1 (3), 188-198, 2019 | 113 | 2019 |
| Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use JK Dyson, J Hutchinson, L Harrison, O Rotimi, D Tiniakos, GR Foster, ... Journal of hepatology 64 (1), 234-238, 2016 | 110 | 2016 |
| Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification JK Dyson, S McPherson, QM Anstee Journal of clinical pathology 66 (12), 1033-1045, 2013 | 90 | 2013 |
| Summary of the British Transplantation Society UK guidelines for hepatitis E and solid organ transplantation S McPherson, AM Elsharkawy, M Ankcorn, S Ijaz, J Powell, I Rowe, ... Transplantation 102 (1), 15-20, 2018 | 74 | 2018 |
